{"id":"rhpsma-7-3-18f-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to PSMA, a protein overexpressed in prostate cancer cells, allowing for visualization of PSMA-positive lesions. This enables accurate diagnosis and staging of prostate cancer.","oneSentence":"rhPSMA-7.3 (18F) Injection is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:03.197Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diagnostic imaging of prostate cancer"}]},"trialDetails":[{"nctId":"NCT05678322","phase":"PHASE3","title":"Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-01-31","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT07011342","phase":"NA","title":"Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2025-10-01","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT05413850","phase":"PHASE1, PHASE2","title":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","status":"RECRUITING","sponsor":"Blue Earth Therapeutics Ltd","startDate":"2022-07-20","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC","enrollment":82},{"nctId":"NCT07285057","phase":"PHASE2","title":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-02-10","conditions":"Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma","enrollment":120},{"nctId":"NCT03995888","phase":"PHASE1","title":"Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2019-06-11","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT04186845","phase":"PHASE3","title":"Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2020-05-04","conditions":"Prostate Cancer","enrollment":391},{"nctId":"NCT06580015","phase":"NA","title":"[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-03-25","conditions":"Prostate Carcinoma","enrollment":20},{"nctId":"NCT04186819","phase":"PHASE3","title":"Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2020-03-02","conditions":"Prostate Cancer","enrollment":356},{"nctId":"NCT05799248","phase":"PHASE3","title":"Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management","status":"RECRUITING","sponsor":"MidLantic Urology","startDate":"2023-04-27","conditions":"Prostate Cancer","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["flotufolastat F18","No other interventions","radiohybrid PSMA-targeted PET imaging agent, Radioligand for PET CT scanning"],"phase":"phase_3","status":"active","brandName":"rhPSMA-7.3 (18F) Injection","genericName":"rhPSMA-7.3 (18F) Injection","companyName":"Blue Earth Diagnostics","companyId":"blue-earth-diagnostics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rhPSMA-7.3 (18F) Injection is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging. Used for Diagnostic imaging of prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}